A new trading day began on Tuesday, with Day One Biopharmaceuticals Inc (NASDAQ: DAWN) stock price up 2.30% from the previous day of trading, before settling in for the closing price of $14.81. DAWN’s price has ranged from $10.90 to $18.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 67.83%. With a float of $68.16 million, this company’s outstanding shares have now reached $87.23 million.
The extent of productivity of a business whose workforce counts for 155 workers is very important to gauge. In terms of profitability, gross margin is 90.66%, operating margin of -733.66%, and the pretax margin is -290.14%.
Day One Biopharmaceuticals Inc (DAWN) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Day One Biopharmaceuticals Inc is 32.41%, while institutional ownership is 64.27%. The most recent insider transaction that took place on Oct 31 ’24, was worth 8,010. In this transaction HEAD OF R&D of this company sold 500 shares at a rate of $16.02, taking the stock ownership to the 1,097,035 shares. Before that another transaction happened on Oct 31 ’24, when Company’s Officer proposed sale 30,000 for $14.47, making the entire transaction worth $434,100.
Day One Biopharmaceuticals Inc (DAWN) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 67.83% per share during the next fiscal year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Here are Day One Biopharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 14.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.01, a number that is poised to hit -0.57 in the next quarter and is forecasted to reach -1.10 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
The latest stats from [Day One Biopharmaceuticals Inc, DAWN] show that its last 5-days average volume of 1.89 million was superior to 0.94 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 38.59%. Additionally, its Average True Range was 0.73.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 66.74%, which indicates a significant increase from 51.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 21.26% in the past 14 days, which was lower than the 44.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.23, while its 200-day Moving Average is $14.62. Now, the first resistance to watch is $15.42. This is followed by the second major resistance level at $15.70. The third major resistance level sits at $16.20. If the price goes on to break the first support level at $14.65, it is likely to go to the next support level at $14.15. Assuming the price breaks the second support level, the third support level stands at $13.88.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
With a market capitalization of 1.53 billion, the company has a total of 100,846K Shares Outstanding. Currently, annual sales are 0 K while annual income is -188,920 K. The company’s previous quarter sales were 93,760 K while its latest quarter income was 37,040 K.
